Eritoran

From Self-sufficiency
Revision as of 15:27, 29 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Eritoran
File:Eritoran skeletal.svg
Systematic (IUPAC) name
Tetrasodium [(2R,3R,4R,5S,6R)-4-decoxy-5-hydroxy-6-[[(2R,3R,4R,5S,6R)-4-[(3R)-3-methoxydecoxy]-6-(methoxymethyl)-3-[[(Z)-octadec-11-enoyl]amino]-5-phosphonatooxyoxan-2-yl]oxymethyl]-3-(3-oxotetradecanoylamino)oxan-2-yl] phosphate
Clinical data
Routes of
administration		 intravenous injection
Legal status
Legal status
  • Investigational
Identifiers
CAS Number 185954-98-7
185955-34-4 (free acid)
ATC code none
PubChem CID 6450173
Synonyms E 5564
Chemical data
Formula C66H122N2Na4O19P2
Molar mass 1401.583 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Eritoran is an investigational drug for the treatment of severe sepsis, an excessive inflammatory response to an infection. It is being developed by Eisai Co.[1][2] As of December 2009, a Phase III clinical trial is recruiting patients.[3]

Mechanism of action

Toll-like receptors (TLRs) play an important role in the innate immune system. They recognise microbes and activate inflammatory immune responses. Toll-like receptor 4 (TLR4) detects lipopolysaccharides found in most Gram-negative bacteria.[4]

Because of its similarity to the lipopolysaccharide lipid A, eritoran acts as TLR4 antagonist and so blocks the excessive reaction triggered by this receptor.[2][5]

File:Lipid A.png
Lipid A as found in E. coli, a gram-negative bacterium
File:Eritoran acid skeletal.svg
Eritoran (free acid)

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


40px This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it.
  1. ↑ "Eritoran: A Potential Therapeutic Agent In Severe Sepsis". MediNEWS.Direct. 17 October 2007. Retrieved 26 December 2009. 
  2. ↑ 2.0 2.1 Kiemer, Alexandra K. (2008). "TLR eröffnen neue Möglichkeiten". Pharmazeutische Zeitung online (in German). Govi-Verlag. Retrieved 26 December 2009. 
  3. ↑ ClinicalTrials.gov NCT00334828 ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis
  4. ↑ "Entrez Gene: TLR4 toll-like receptor 4". 
  5. ↑ Tidswell, M; Tillis, W; Larosa, SP; Lynn, M; Wittek, AE; Kao, R; Wheeler, J; Gogate, J; Opal, SM (2010). "Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis". Critical care medicine. 38 (1): 72–83. doi:10.1097/CCM.0b013e3181b07b78. PMID 19661804. 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Eritoran&oldid=23867"